Table 1.
Baseline demographics and disease characteristics
| Characteristic | All patients | Prior cetuximab use | All patients with local recurrence | Prior neck dissection | ||
|---|---|---|---|---|---|---|
| With | Without | With | Without | |||
| All patients, N (%) | 256 (100.0) | 155 (100.0) | 101 (100.0) | 50 (100.0) | 19 (100.0) | 31 (100.0) |
| Sex | ||||||
| Male, n (%) | 202 (78.9) | 129 (83.2) | 73 (72.3) | 35 (70.0) | 15 (78.9) | 20 (64.5) |
| Age, median (range), years | 66 (20–84) | 66 (20–84) | 66 (24–80) | 66 (29–78) | 63 (34–72) | 67 (29–78) |
| ≥ 75 years, n (%) | 24 (9.4) | 13 (8.4) | 11 (10.9) | 5 (10.0) | 0 (0.0) | 5 (16.1) |
| ECOG PS, n (%) | ||||||
| 0 | 118 (46.1) | 67 (43.2) | 51 (50.5) | 24 (48.0) | 9 (47.4) | 15 (48.4) |
| 1 | 97 (37.9) | 64 (41.3) | 33 (32.7) | 17 (34.0) | 7 (36.8) | 10 (32.3) |
| ≥ 2a | 31 (12.1) | 20 (12.9) | 11 (10.9) | 6 (12) | 2 (10.5) | 4 (12.9) |
| Unknown | 10 (3.9) | 4 (2.6) | 6 (5.9) | 3 (6.0) | 1 (5.3) | 2 (6.5) |
| Nivolumab treatment line, n (%) | ||||||
| 1st line | 70 (27.3) | 9 (5.8) | 61 (60.4) | 15 (30.0) | 6 (31.6) | 9 (29.0) |
| 2nd line | 110 (43.0) | 86 (55.5) | 24 (23.8) | 20 (40.0) | 7 (36.8) | 13 (41.9) |
| ≥ 3rd line | 76 (29.7) | 60 (38.7) | 16 (15.8) | 15 (30.0) | 6 (31.6) | 9 (29.0) |
| Primary tumor site, n (%) | ||||||
| Maxillary sinusa | 14 (5.5) | 10 (6.5) | 4 (4.0) | 5 (10.0) | 1 (5.3) | 4 (12.9) |
| Oral cavity | 56 (21.9) | 30 (19.4) | 26 (25.7) | 13 (26.0) | 10 (52.6) | 3 (9.7) |
| Salivary glanda | 23 (9.0) | 10 (6.5) | 13 (12.9) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Larynx | 21 (8.2) | 15 (9.7) | 6 (5.9) | 4 (8.0) | 1 (5.3) | 3 (9.7) |
| Nasopharynxa | 19 (7.4) | 7 (4.5) | 12 (11.9) | 3 (6.0) | 0 (0.0) | 3 (9.7) |
| Oropharynx | 40 (15.6) | 26 (16.8) | 14 (13.9) | 11 (22.0) | 4 (21.1) | 7 (22.6) |
| Hypopharynx | 64 (25.0) | 48 (31.0) | 16 (15.8) | 9 (18.0) | 3 (15.8) | 6 (19.4) |
| Others | 19 (7.4) | 9 (5.8) | 10 (9.9) | 5 (10.0) | 0 (0.0) | 5 (16.1) |
ECOG PS Eastern Cooperative Oncology Group performance status
aNot included in CheckMate 141 [4]